PMID: 11905614Mar 22, 2002Paper

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

The Lancet Oncology
S R Johnston

Abstract

Activating oncogenic mutations of the RAS gene are common in cancer, occurring in 30% of solid tumours in adults. Inhibitors of the enzyme farnesyl protein transferase prevent a key step in the post-translational processing of the RAS protein, and were developed initially as a therapeutic strategy to inhibit cell signalling in RAS-transformed cells. As more has been learnt about the biological effects of farnesyl transferase inhibitors on cancer cells, it has become increasingly clear that tumours without oncogenic RAS mutations may also be targets for farnesyl transferase inhibitor therapy. Encouraging results from phase I and II clinical trials have emerged, creating both enthusiasm and new challenges for the optimum clinical development of this important new class of anticancer drug.

References

Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·K KatoC J Der
Mar 1, 1989·Japanese Journal of Cancer Research : Gann·H TsudaM Terada
Jan 1, 1987·Annual Review of Biochemistry·M Barbacid
Jul 1, 1995·Breast Cancer Research and Treatment·G J Clark, C J Der
Apr 7, 1995·The Journal of Biological Chemistry·S A ArmstrongM S Brown
Sep 1, 1994·Current Biology : CB·T KodakiP J Parker
Feb 1, 1994·The Journal of Cell Biology·S M Frisch, H Francis
Feb 1, 1994·Current Opinion in Genetics & Development·F McCormick
Sep 1, 1993·Molecular Biology of the Cell·J E MeredithM A Schwartz
Jan 1, 1993·Annual Review of Biochemistry·D R Lowy, B M Willumsen
Mar 8, 1996·The Journal of Biological Chemistry·P J Casey, M C Seabra
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·G JamesM S Brown
Aug 1, 1996·Nature Structural Biology·F McCormick
Sep 12, 1996·Nature·C J Marshall
Mar 15, 1997·Genes & Development·S G KennedyN Hay
Aug 8, 1997·Biochimica Et Biophysica Acta·A D Cox, C J Der
Sep 25, 1997·Journal of Medicinal Chemistry·D M Leonard
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·M M MoasserN Rosen
Aug 1, 1998·The Journal of Biological Chemistry·L Sepp-Lorenzino, N Rosen
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·N SuzukiF Tamanoi
May 1, 1990·Physical Review. a·Y P Varshni
Jan 23, 1999·Oncogene·R J MuschelE J Bernhard
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyD D Von Hoff
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ZujewskiK H Cowan

❮ Previous
Next ❯

Citations

Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Keiran S M Smalley, Tim G Eisen
Dec 7, 2007·Archivum Immunologiae Et Therapiae Experimentalis·Amélie MarquetteNicolas Dumaz
Dec 22, 2004·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Sérgio Filipe SousaMaria João Ramos
Oct 9, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C Avendaño, J C Menéndez
Mar 12, 2004·Cancer Letters·Ana Ramírez de MolinaJuan Carlos Lacal
Mar 12, 2004·Cancer Letters·Julien MazieresGilles Favre
May 14, 2005·Pharmacology & Therapeutics·Thomas Efferth, Manfred Volm
Mar 21, 2002·The Lancet Oncology·Paul D Nathan, Tim G Eisen
Jul 20, 2002·Current Opinion in Pharmacology·Srinivasan Madhusudan, Adrian L Harris
Dec 4, 2008·Asian Journal of Andrology·Noel W ClarkeMick D Brown
Oct 11, 2002·Nature·Stephen B LongLorena S Beese
Nov 1, 2001·Proceedings of the National Academy of Sciences of the United States of America·S B LongL S Beese
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helen J MackayJaap Verweij
Jan 5, 2012·Dermatology Research and Practice·Felipe Ades, Otto Metzger-Filho
Dec 11, 2002·Expert Opinion on Therapeutic Targets·John T Lee, James A McCubrey
Jun 5, 2003·Expert Opinion on Investigational Drugs·Rita NahtaFrancisco J Esteva
Jun 5, 2003·Expert Opinion on Investigational Drugs·Peter M Fischer, Athos Gianella-Borradori
Jun 6, 2008·Expert Opinion on Drug Delivery·Johannes KohlschütterMartin Trepel
Jul 31, 2008·Cancer Investigation·Tianhong Li, Joseph A Sparano
Mar 15, 2003·Clinical Breast Cancer·Tianhong Li, Joseph A Sparano
Mar 7, 2003·Clinical Colorectal Cancer·Daniel B LongleyPatrick G Johnston
Dec 19, 2006·Phytochemistry·Véronique EparvierMarc Litaudon
Jun 12, 2004·EMBO Reports·Christel BoutonnetStéphan Vagner
May 18, 2006·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·R AgarwalS B Kaye
Dec 13, 2005·Critical Reviews in Oncology/hematology·Giampietro GaspariniGiuseppe Toffoli
Jun 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Mehmet Topcul, Idil Cetin
Sep 1, 2004·The Lancet Oncology·Mary J MacKenzie
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen R D JohnstonAngela Howes
Dec 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Todd M ZimmermanThomas F Gajewski
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathrin Strasser-Weippl, Paul E Goss
Dec 4, 2003·Bioorganic & Medicinal Chemistry Letters·Patrick AngibaudWalter Wouters
Mar 3, 2005·Journal of Pharmaceutical and Biomedical Analysis·Laurence GoossensJean-François Goossens
Nov 8, 2002·British Medical Bulletin·Johann S de Bono, Eric K Rowinsky

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.